350 related articles for article (PubMed ID: 24699629)
1. Helper T-cell differentiation in graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Fu J; Heinrichs J; Yu XZ
Arch Immunol Ther Exp (Warsz); 2014 Aug; 62(4):277-301. PubMed ID: 24699629
[TBL] [Abstract][Full Text] [Related]
2. T Cell Subsets in Graft Versus Host Disease and Graft Versus Tumor.
Jiang H; Fu D; Bidgoli A; Paczesny S
Front Immunol; 2021; 12():761448. PubMed ID: 34675938
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
Tian Y; Deng YB; Huang YJ; Wang Y
Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation.
Dander E; Balduzzi A; Zappa G; Lucchini G; Perseghin P; Andrè V; Todisco E; Rahal D; Migliavacca M; Longoni D; Solinas G; Villa A; Berti E; Mina PD; Parma M; Allavena P; Biagi E; Rovelli A; Biondi A; D'Amico G
Transplantation; 2009 Dec; 88(11):1261-72. PubMed ID: 19996925
[TBL] [Abstract][Full Text] [Related]
5. The important balance between cytokines derived from type 1 and type 2 helper T cells in the control of graft-versus-host disease.
Tanaka J; Imamura M; Kasai M; Hashino S; Kobayashi S; Noto S; Higa T; Sakurada K; Asaka M
Bone Marrow Transplant; 1997 Mar; 19(6):571-6. PubMed ID: 9085737
[TBL] [Abstract][Full Text] [Related]
6. T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?
Campe J; Ullrich E
Front Immunol; 2021; 12():806529. PubMed ID: 35069590
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Targeting the IL17 pathway for the prevention of graft-versus-host disease.
van der Waart AB; van der Velden WJ; Blijlevens NM; Dolstra H
Biol Blood Marrow Transplant; 2014 Jun; 20(6):752-9. PubMed ID: 24565991
[TBL] [Abstract][Full Text] [Related]
9. [Effect of donor CD4+CD25+ regulatory T cells on hematopoietic and immune reconstitution, GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation].
Yang K; Fan ZP; Liu QF; Zhang Y
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Apr; 28(4):537-41. PubMed ID: 18495584
[TBL] [Abstract][Full Text] [Related]
10. Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease.
Yi T; Zhao D; Lin CL; Zhang C; Chen Y; Todorov I; LeBon T; Kandeel F; Forman S; Zeng D
Blood; 2008 Sep; 112(5):2101-10. PubMed ID: 18596226
[TBL] [Abstract][Full Text] [Related]
11. Regulatory T cells and IL-17-producing cells in graft-versus-host disease.
Teshima T; Maeda Y; Ozaki K
Immunotherapy; 2011 Jul; 3(7):833-52. PubMed ID: 21751953
[TBL] [Abstract][Full Text] [Related]
12. Recent Metabolic Advances for Preventing and Treating Acute and Chronic Graft Versus Host Disease.
Mohamed FA; Thangavelu G; Rhee SY; Sage PT; O'Connor RS; Rathmell JC; Blazar BR
Front Immunol; 2021; 12():757836. PubMed ID: 34712243
[TBL] [Abstract][Full Text] [Related]
13. A subset of CD8+ T cells acquiring selective suppressive properties may play a role in GvHD management.
Avivi I; Stroopinsky D; Rowe JM; Katz T
Transpl Immunol; 2013 Jan; 28(1):57-61. PubMed ID: 23196257
[TBL] [Abstract][Full Text] [Related]
14. Targeting Inflammatory T Helper Cells
Buchele V; Abendroth B; Büttner-Herold M; Vogler T; Rothamer J; Ghimire S; Ullrich E; Holler E; Neurath MF; Hildner K
Front Immunol; 2018; 9():1138. PubMed ID: 29910804
[TBL] [Abstract][Full Text] [Related]
15. Low percentages of circulating CD8(+)/CD45RA(+) human T lymphocytes expressing beta7 integrin correlate with the occurrence of intestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Avanzini MA; Maccario R; Locatelli F; Giebel S; Santos CD; Bernardo ME; Pagliara D; Montagna D; Longo S; Amendola G; Marconi M
Exp Hematol; 2006 Oct; 34(10):1429-34. PubMed ID: 16982336
[TBL] [Abstract][Full Text] [Related]
16. Biological advances in acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Duran-Struuck R; Reddy P
Transplantation; 2008 Feb; 85(3):303-8. PubMed ID: 18301323
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
18. A promising sword of tomorrow: Human γδ T cell strategies reconcile allo-HSCT complications.
Hu Y; Cui Q; Luo C; Luo Y; Shi J; Huang H
Blood Rev; 2016 May; 30(3):179-88. PubMed ID: 26654098
[TBL] [Abstract][Full Text] [Related]
19. [The role of CD4+ CD25+ T cell and FOXP3 in hsot acute graft rejection].
Liu YJ; Wu DP; Li CX; He J; Qiu QC; Zhang XG
Zhonghua Nei Ke Za Zhi; 2006 Oct; 45(10):835-8. PubMed ID: 17217750
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between WT1-specific T-cell subsets and graft-versus-host disease after nonmyeloablative allogeneic transplantation].
Wei L; Zuo HL; Liu TQ; Sun XD; Guo M; Liu GX; Sun QY; Qiao JH; Wang DH; Yu CL; Hu KX; Dong Z; Ai HS
Zhonghua Xue Ye Xue Za Zhi; 2011 Feb; 32(2):89-93. PubMed ID: 21429373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]